Other potential diagnostic applications of AGR2 IHC may include the distinction of renal cell carcinomas (usually negative) from urothelial carcinomas (usually positive) from the kidney and mesotheliomas (usually negative) from adenocarcinomas (usually positive) of the lung. This evidence concerns the gene AGR2 and urothelial carcinoma.